Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Liabilities and Shareholders Equity (2022 - 2025)

Jin Medical International's Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $45.8 million for Q3 2024.

  • For Q3 2024, Liabilities and Shareholders Equity rose 39.2% year-over-year to $45.8 million; the TTM value through Sep 2025 reached $99.6 million, changed N/A, while the annual FY2024 figure was $45.8 million, 39.2% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2024 was $45.8 million at Jin Medical International, up from $32.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $45.8 million in Q3 2024 and bottomed at $20.9 million in Q3 2022.
  • The 3-year median for Liabilities and Shareholders Equity is $32.9 million (2023), against an average of $33.2 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 57.14% in 2023 before it skyrocketed 39.2% in 2024.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $20.9 million in 2022, then surged by 57.14% to $32.9 million in 2023, then surged by 39.2% to $45.8 million in 2024.
  • Per Business Quant, the three most recent readings for ZJYL's Liabilities and Shareholders Equity are $45.8 million (Q3 2024), $32.9 million (Q3 2023), and $20.9 million (Q3 2022).